HealthdirectFree Australian health advice you can count on.

• Male patients with female partners of childbearing age should use effective contraceptive measures during the apalutamide therapy and for at least three months after stopping the therapy. • Monitor patients for routine bone density assessment as apalutamide is associated with episodes of frequent falls and fracture.‍‍‍‍‍‍​​​‍​​​​​​ Care should be taken in patients who are at risk for fracture. • Patients should be continuously observed for the occurrence of seizures during the treatment with apalutamide. If seizures occur during treatment, apalutamide should be discontinued permanently. • Evaluate thyroid function and assess the level of thyroid stimulating hormone (TSH) in patients taking apalutamide to detect the risk of developing hypothyroidism. • Monitor blood cell counts regularly for detecting blood abnormalities such as decreased number of red blood cells, lymphocytes, and white blood cells. • Patients under apalutamide therapy should be treated accordingly if they show signs of high blood pressure , increased blood sugar levels, and high potassium levels.